Oncodesign Services announce access to ImaginAb’s CD8 ImmunoPET technology
Oncodesign Services and ImaginAb sign a Preclinical License and Supply Agreement
Oncodesign Services and ImaginAb sign a Preclinical License and Supply Agreement
Under the terms of the collaboration, Vertex and Lonza will partner in the process development and scale-up for the manufacturing of the product portfolio and co-invest to build a dedicated new facility in Portsmouth, New Hampshire (US)
LITFULO is the first and only treatment for severe alopecia areata approved for patients as young as 12
Dr. Reddy's aims to roll out its trade generics across cities and towns in India
Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn’s disease and other autoimmune conditions
Investment enables development of revolutionary multi-omic platform using super-resolution imaging technology for earlier disease detection and accelerated discovery of therapeutics
Total investments could reach €70 million, of which approximately 15% in R&D and 85% in capex, that would be deployed from 2026
This fresh infusion of capital will enable ImmunoACT to fast track the additional supply of the lead candidate HCAR-19
These announcements are in line with Croda Pharma’s strategy to “Empower Biologics Delivery” and follows news on investments, earlier this year, to expand Croda Pharma’s global manufacturing capabilities to enable the next generation vaccines and therapeutic drugs.
Subscribe To Our Newsletter & Stay Updated